-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Roche announced the positive results of its CD20 antibody Ocrevus (ocrelizumab) in the treatment of patients with early multiple sclerosis (MS).
Multiple sclerosis (MS) is a chronic autoimmune disease caused by the immune system attacking the myelin sheath that protects nerves.
Ocrevus is a humanized monoclonal antibody targeting CD20 positive B cells.
In the Phase 3 clinical trial called ENSEMBLE, patients who were newly diagnosed and had not yet received pre-disease modification therapy (DMT) received Ocrevus treatment.
"All MS patients, regardless of the type of disease they have, will experience disease progression.
▽ attention [drug Mingkang Germany ] micro-channel public number
[Medical attention Mingkang Germany ] ] micro-channel public number